Bioventus (NASDAQ:BVS) Earns "Sell (D-)" Rating from Weiss Ratings

Key Points

• Bioventus (NASDAQ:BVS) received a "sell (D-)" rating from Weiss Ratings, indicating a negative outlook from analysts.
• Despite the bleak rating from Weiss, Wall Street Zen upgraded Bioventus from a "buy" to a "strong-buy" rating on August 9th.
• The company's stock is currently priced at $6.76, having fluctuated between a 12-month low of $5.81 and a high of $14.38.

Bioventus (NASDAQ:BVS - Get Free Report)'s stock had its "sell (d-)" rating reissued by equities research analysts at Weiss Ratings in a research report issued on Wednesday,Weiss Ratings reports.

Separately, Wall Street Zen upgraded Bioventus from a "buy" rating to a "strong-buy" rating in a research note on Saturday, August 9th. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat, Bioventus has a consensus rating of "Sell".

Bioventus Price Performance

Shares of BVS stock traded up $0.11 during trading hours on Wednesday, reaching $6.76. The company had a trading volume of 167,669 shares, compared to its average volume of 387,582. Bioventus has a 12 month low of $5.81 and a 12 month high of $14.38. The company has a current ratio of 1.48, a quick ratio of 0.96 and a debt-to-equity ratio of 1.48. The firm has a fifty day moving average of $7.02. The company has a market capitalization of $558.92 million, a P/E ratio of 13.58 and a beta of 0.81.

Bioventus (NASDAQ:BVS - Get Free Report) last posted its earnings results on Wednesday, August 6th. The company reported $0.21 earnings per share for the quarter, missing analysts' consensus estimates of $0.22 by ($0.01). Bioventus had a negative net margin of 0.03% and a positive return on equity of 23.04%.

About Bioventus

Bioventus Inc a medical device company, focuses on developing and commercializing clinically treatments that engage and enhance the body's natural healing process in the United States and internationally. The company's portfolio of products includes pain treatments, which comprise non-surgical joint pain injection therapies, as well as peripheral nerve stimulation products.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.